Compare Stocks → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADGINASDAQ:HLVXNASDAQ:MGTXNASDAQ:TARS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADGIAdagio Therapeutics$4.21$2.41▼$78.82$504.98MN/A2.27 million shs22,357 shsHLVXHilleVax$14.00+1.4%$15.56$9.94▼$20.22$696.08M0.79134,909 shs35,809 shsMGTXMeiraGTx$5.32+4.9%$5.71$3.49▼$8.35$342.13M1.31149,927 shs108,587 shsTARSTarsus Pharmaceuticals$38.08+2.8%$34.28$12.57▼$40.40$1.44B1.1707,208 shs369,676 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADGIAdagio Therapeutics0.00%0.00%0.00%0.00%0.00%HLVXHilleVax+1.40%+3.92%-4.96%-8.61%-2.13%MGTXMeiraGTx+1.30%+3.16%-7.91%-21.84%-17.64%TARSTarsus Pharmaceuticals+0.49%+15.29%+6.59%+25.10%+141.24%Global crypto currency reset (41 major banks signed up) (Ad)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADGIAdagio TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AHLVXHilleVax3.2874 of 5 stars3.53.00.00.03.15.00.0MGTXMeiraGTx3.8445 of 5 stars3.53.00.04.80.01.70.6TARSTarsus Pharmaceuticals2.9625 of 5 stars4.40.00.00.02.53.30.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADGIAdagio TherapeuticsN/AN/AN/AN/AHLVXHilleVax3.00Buy$30.67119.05% UpsideMGTXMeiraGTx3.00Buy$25.67382.46% UpsideTARSTarsus Pharmaceuticals2.88Moderate Buy$48.3827.04% UpsideCurrent Analyst RatingsLatest MGTX, HLVX, ADGI, and TARS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2024HLVXHilleVaxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.003/15/2024MGTXMeiraGTxRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.003/6/2024TARSTarsus PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.00 ➝ $44.002/29/2024TARSTarsus PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$19.00 ➝ $30.002/28/2024TARSTarsus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$50.00 ➝ $57.002/28/2024TARSTarsus PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$40.00 ➝ $50.002/28/2024TARSTarsus PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$55.00 ➝ $59.00(Data available from 5/7/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADGIAdagio TherapeuticsN/AN/AN/AN/A$5.02 per shareN/AHLVXHilleVaxN/AN/AN/AN/A$5.48 per shareN/AMGTXMeiraGTx$14.02M24.40N/AN/A$2.17 per share2.45TARSTarsus Pharmaceuticals$17.45M82.44N/AN/A$5.95 per share6.40Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADGIAdagio Therapeutics-$226.79M-$3.15N/AN/AN/AN/A-57.14%-50.28%N/AHLVXHilleVax-$123.57M-$3.04N/AN/AN/AN/A-48.17%-38.05%5/10/2024 (Estimated)MGTXMeiraGTx-$84.03M-$1.47N/A5.91N/A-599.47%-114.33%-42.56%5/9/2024 (Estimated)TARSTarsus Pharmaceuticals-$135.89M-$4.64N/AN/AN/AN/A-74.28%-58.20%5/8/2024 (Confirmed)Latest MGTX, HLVX, ADGI, and TARS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2024N/ATARSTarsus Pharmaceuticals-$1.15N/A+$1.15N/AN/AN/A 3/20/2024Q4 2023HLVXHilleVax-$0.80-$0.78+$0.02-$0.78N/AN/A3/14/2024Q4 2023MGTXMeiraGTx-$0.46-$0.47-$0.01-$1.36$10.13 million$2.04 million2/27/202412/31/2023TARSTarsus Pharmaceuticals-$1.37-$1.31+$0.06-$1.31$4.63 million$13.08 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADGIAdagio TherapeuticsN/AN/AN/AN/AN/AHLVXHilleVaxN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADGIAdagio TherapeuticsN/A7.097.09HLVXHilleVax0.1010.6210.62MGTXMeiraGTx0.622.382.38TARSTarsus Pharmaceuticals0.156.936.85OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADGIAdagio Therapeutics96.94%HLVXHilleVax86.42%MGTXMeiraGTx67.48%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipADGIAdagio TherapeuticsN/AHLVXHilleVax29.30%MGTXMeiraGTx9.70%TARSTarsus Pharmaceuticals11.54%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADGIAdagio Therapeutics2,021108.83 millionN/ANot OptionableHLVXHilleVax9049.72 million35.15 millionNot OptionableMGTXMeiraGTx41964.31 million58.07 millionOptionableTARSTarsus Pharmaceuticals24437.78 million33.42 millionOptionableMGTX, HLVX, ADGI, and TARS HeadlinesSourceHeadlineDoes Tarsus Pharmaceuticals (TARS) Have the Potential to Rally 38.7% as Wall Street Analysts Expect?zacks.com - May 6 at 10:56 AMTarsus Pharmaceuticals (TARS) to Release Quarterly Earnings on Wednesdaymarketbeat.com - May 2 at 10:00 AMTarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024globenewswire.com - May 1 at 5:00 PMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Legend Biotech (LEGN), Organon (OGN) and Exelixis (EXEL)markets.businessinsider.com - May 1 at 8:37 AMabrdn plc Purchases New Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)marketbeat.com - April 30 at 4:59 AMMaáza Martinlatimes.com - April 28 at 8:51 AMTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Vivo Capital LLCmarketbeat.com - April 27 at 9:40 PMThe bottom line about ticksmeridianstar.com - April 26 at 3:13 AMAnalysts Conflicted on These Healthcare Names: Amneal Pharmaceuticals (AMRX) and Community Health (CYH)markets.businessinsider.com - April 25 at 10:18 AMBioPharma Credit to loan USD100 million to Tarsus Pharmaceuticalslse.co.uk - April 24 at 8:59 AMBuy Rating Affirmed for Tarsus Pharmaceuticals Amidst Strategic Debt Refinancing and Strong Financial Outlookmarkets.businessinsider.com - April 24 at 3:59 AMTarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakonglobenewswire.com - April 23 at 8:30 AMTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock Holdings Trimmed by Allspring Global Investments Holdings LLCmarketbeat.com - April 20 at 5:14 AMInsider Returns Down To US$166k As Tarsus Pharmaceuticals' Stock Dips 14%finance.yahoo.com - April 19 at 8:16 AMQ1 2024 EPS Estimates for Tarsus Pharmaceuticals, Inc. Boosted by Analyst (NASDAQ:TARS)marketbeat.com - April 19 at 8:16 AMVanguard Group Inc. Has $27.58 Million Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)marketbeat.com - April 13 at 4:30 AMTarsus Pharmaceuticals (NASDAQ:TARS) Trading Down 5.2%marketbeat.com - April 12 at 2:51 PMTarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Up 6.1%marketbeat.com - April 11 at 4:01 PMWall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Knowfinance.yahoo.com - April 8 at 2:09 PMWall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Knowzacks.com - April 8 at 10:56 AMScientists share trial results for new tick-repelling drug for humans: 'An amazing opportunity'msn.com - April 6 at 2:18 AMTarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Whyzacks.com - April 1 at 1:00 PMTarsus Pharmaceuticals executive sells over $130k in company stockinvesting.com - March 21 at 8:19 PMTarsus Pharmaceuticals exec sells over $135k in stockinvesting.com - March 21 at 8:19 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAdagio TherapeuticsNASDAQ:ADGIAdagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.HilleVaxNASDAQ:HLVXHilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.MeiraGTxNASDAQ:MGTXMeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Tarsus PharmaceuticalsNASDAQ:TARSTarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.